Related references
Note: Only part of the references are listed.Antifungal prophylaxis with liposomal amphotericin B and caspofungin in high-risk patients after liver transplantation: impact on fungal infections and immune system
A. Perrella et al.
INFECTIOUS DISEASES (2016)
Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis
Jesus Fortun et al.
LIVER TRANSPLANTATION (2016)
A Complete Treatment of Adult Living Donor Liver Transplantation: A Review of Surgical Technique and Current Challenges to Expand Indication of Patients
S. -G. Lee
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients
Faouzi Saliba et al.
CLINICAL INFECTIOUS DISEASES (2015)
Randomized, Double-Blind Trial of Anidulafungin Versus Fluconazole for Prophylaxis of Invasive Fungal Infections in High-Risk Liver Transplant Recipients
D. J. Winston et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Micafungin Versus Amphotericin B Lipid Complex for the Prevention of Invasive Fungal Infections in High-Risk Liver Transplant Recipients
Hsin-Yun Sun et al.
TRANSPLANTATION (2013)
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
O. A. Cornely et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
The risk factors of fungal infection in living-donor liver transplantations
Takao Ohkubo et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2012)
Echinocandin Antifungal Drugs in Fungal Infections A Comparison
Sharon C. -A. Chen et al.
DRUGS (2011)
CONSORT 2010 Statement Updated Guidelines for Reporting Parallel Group Randomized Trials
Kenneth F. Schulz et al.
OBSTETRICS AND GYNECOLOGY (2010)
Management of Drug and Food Interactions with Azole Antifungal Agents in Transplant Recipients
Elizabeth Dodds-Ashley
PHARMACOTHERAPY (2010)
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Outcomes of antifungal prophylaxis in high-risk liver transplant recipients
S. Hadley et al.
TRANSPLANT INFECTIOUS DISEASE (2009)
Antifungal management practices in liver transplant recipients
N. Singh et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben De Pauw et al.
CLINICAL INFECTIOUS DISEASES (2008)
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Ernst-Ruediger Kuse et al.
LANCET (2007)
Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study
J Gavalda et al.
CLINICAL INFECTIOUS DISEASES (2005)
Low-dose arnphotericin for prevention of serious fungal infection following liver transplantation
T Shah et al.
TRANSPLANT INFECTIOUS DISEASE (2005)
Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study
NA Kartsonis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation
JAH van Burik et al.
CLINICAL INFECTIOUS DISEASES (2004)
Global distribution and outcomes for Candida species causing invasive candidiasis:: Results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis
AL Colombo et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2003)
Comparison of caspofungin and amphotericin B for invasive candidiasis.
J Mora-Duarte et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Clinical efficacy of echinocandin antifungals
EG Arathoon
CURRENT OPINION IN INFECTIOUS DISEASES (2001)
Update on antifungals targeted to the cell wall:: focus on β-1,3-glucan synthase inhibitors
NH Georgopapadakou
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide
H Mikamo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Share Paper
